EpiAxis Therapeutics

EpiAxis develops reversible cyclic peptide inhibitors of LSD1 to overcome treatment resistance in prostate, small cell lung and colorectal cancers. It needed a site that investors, clinicians and partners could understand in one visit.

The science is deep and the audience is mixed: investors deciding on a raise, clinicians checking the evidence and research partners such as the University of Canberra and ANU. The old site was hard to update and said little about the pipeline.

1. Story and structure

   Turned the science into a clear path: the problem of resistance, the LSD1 approach, the pipeline, the team and how to collaborate.

2. Website and CMS

   A new site on Next.js and Payload CMS, with on-page editing so the team can update milestones and news themselves.

3. Search and sharing

   Structured data, generated share cards, an llms.txt file and production-only indexing, so the right pages show up in search and AI answers.

A fast site the EpiAxis team edits themselves, built to explain the science to every audience.